Oncomed Sets Price Range; Seeks $60M in Proposed IPO
By Jennifer Boggs
Thursday, July 11, 2013
More than a year after filing an S-1 for an initial public offering (IPO), Oncomed Pharmaceuticals Inc. set proposed terms, seeking to sell 4 million shares priced between $14 and $16.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.